RSS Feed For (NASDAQ:ARNA)

ARENA PHARMAC (NASDAQ:ARNA)

3.19 -0 (-0%)
ARENA PHARMAC (NASDAQ:ARNA) Delayed :
Previous Close $3.19    52 Week High $7.42 
Open $3.10    52 Week Low $2.26 
Day High $3.25    P/E N/A 
Day Low $3.09    EPS $-2.38 
Volume 1,165,410       
More ARNA Info: Chart SEC Filings Profile Historical Options

What is this?Friends, Peers and Foes

Ticker # Stories Ticker # Stories
VVUS 4 LNC 3
ANPI 3 BAC 3
DRYS 2 KERX 2
HOLX 2 STEC 2
AUXL 2 C 2
ATEC 2 VPHM 2
View All Friends, Peers and Foes

StreetInsider Reports on ARNA by Category

Comments on recent ARNA articles

ghdhairirons
on Dec 23, 2009
at 08:58 PM
ghdhairirons http://www.ghdhairirons.com/ ghd hair straighteners are in best design. http://www.discountukghd.com/ghd-pure-white-limited-edition-hair-straightenersiv-styler-mk4-p-41.html ghd pure white is 63% off, http://www.discountukghd.com/ghd-purple-limited-edition-hair-straighteners-iv-styler-mk4-p-42.html ghd purple is only $90.http://www.ghdhairirons.com/ ghd hair straighteners are in best design. http://www.discountukghd.com/ghd-pure-white-limited-edition-hair-straightenersiv-styler-mk4-p-41.html ghd pure white is 63% off, http://www.discountukghd.com/ghd-purple-limited-edition-hair-straighteners-iv-styler-mk4-p-42.html ghd purple is only $90.
Article: After-Hours Movers 12/23: MRM, BQI, SLGN Higher; ARNA Lower
chris
on Mar 17, 2009
at 02:08 AM
SEC The SEC doesnt investigate. They are only a cleanup crew. Witness B Maddoff, who, despite hundreds of tips over 5 years, was not turned in until the economy tanked.
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks
JAC47
on Mar 16, 2009
at 06:12 PM
ARNA Analysis The Canaccord analysist must have missed the ARNA business presentation slide 54 (December 2008) below. The FDA required the first phase III Bloom Trial to exclude those with Valvulopathy. However, the FDA allowed patients with existing valvulopathy in the Second pahse III Blossum Trial. They would not have done that if there was any significant signs of risk in the Bloom Trial. Bad call by an analyst with a BA in economics. • BLOOM – 3,182 patients randomized 1:1 during Year 1 to receive placebo or lorcaserin 10 mg BID – Echoes performed at Screening, 6, 12, 18 and 24 months – Patients with FDA valvulopathy excluded – Echo-DSMB reviewed all echoes from 6 and 12 months (unblinded)— differences, if any, between placebo and lorcaserin group were not meaningful • BLOSSOM – 4,008 patients randomized 2:1:2, placebo: lorcaserin 10 mg QD: lorcaserin 10 mg BID – Echoes performed at Baseline, 6 and 12 months – No echo exclusion criteria; FDA valvulopathy allowed – Data will be combined with BLOOM data for integrated analysis with sufficient statistical power to address negotiated endpoint
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks
wasl
on Mar 16, 2009
at 02:07 PM
ARNA This is the broker that obviously is behind the dubious naked shorts, should be investigated by sec!
Article: Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks

Comments on ARNA


No comments are currently available.